A Dose Finding Study of Cannabidiol in Dogs with Intractable Epilepsy

Background and purpose of the trial

Epilepsy is currently reported to affect approximately 5% of the canine population; of that number approximately 30% of dogs are poorly controlled on routine anti-epileptic drugs (AEDs). Recent CBD research has demonstrated the anti-convulsive properties in both canine and human patients; however, to-date a dose finding study has not been performed in veterinary patients. For the initial phase of this study, our primary purpose is to determine a dose of CBD that will reduce the seizure frequency in canine patients to 50% or less.

Study Design

Once it has been verified that initial criteria have been met, dogs will come to CSU to have a neurologic examination, undergo an MRI and CSF tap, and have bloodwork performed, including AED levels, to rule out any obvious causes of epilepsy. At this visit we will also check a CBD level to ensure there’s no current CBD in the system. If a dog has already had an MRI and CSF tap performed recently it will not be necessary to repeat. After the MRI and CSF tap, each dog will be randomly assigned to one of three dosing groups: 5mg/kg, 10mg/kg, or 20mg/kg given twice daily. Over the next 12 weeks, you will bring your dog to CSU for a recheck examination, routine bloodwork, and a CBD level every four weeks. Additionally, at the 12-week time point, all dogs will have a neurological examination performed and AED levels checked.

Commitment

During the 12-week study you are unable to make any changes to your dog’s medications so it’s crucial that you’re comfortable with his or her current medication protocol prior to enrolling. You will be committed to bringing your dog back to CSU every four weeks for the three month study period so that we can obtain blood samples. You will also be committed to filling out a standardized monthly seizure log as necessary along with a weekly behavior survey.

Incentives

All exams and diagnostic testing, including the monthly bloodwork, will be covered by the study. In addition you will receive a $300 credit to your VTH account split into three payments dispersed after each successful appointment.

condition(s)

epilepsy

eligibility information

  • Must be on at least one routine anti-epileptic drug (AED) for at least three months at time of enrollment
  • Must be having two or more seizures per month
  • Must be able to come to CSU every four weeks for 12 weeks
  • Must be willing to fill out a monthly seizure log and a weekly behavior survey
  • Must not have any underlying neurologic conditions that may be a cause of the seizures
  • Must not have any pre-existing liver disease
  • Must not have any other major underlying diseases

Enrollment Deadline

Enrollment ends May 31, 2022

contact information

If you’re interested in enrolling your dog in this study please complete the qualification survey.

CSU ram head with green background
Neurology Clinical Trials

(970) 297-4405

[email protected]